Bayer Intellectual Property Gmbh

Seattle Genetics, Inc.

Sandra Bruder

Simone Greven

Axel Harrenga

Andreas Wilmen

Christoph Freiberg

Mark Trautwein

Andrea Eicker

Christiane Otto

Siegmund Wolf

Joachim Schuhmacher

Hans-Georg Lerchen

Karl-Heinz Thierauch

Beatrix Stelte-Ludwig

Christoph Mahlert

Iring Heisler

Sherif El Sheikh

Sven Golfier

Lars Linden

Jörg Willuda

Hannah Jöriβen

Rudolf Beier

Heike Petrul

Sandra Borkowski

The present invention is directed to the neutralizing prolactin receptor antibody 006-H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.

Neutralizing prolactin receptor antibodies and their therapeutic use

The present invention is directed to the neutralizing prolactin receptor antibody 005-C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.

The present application relates to new binder-drug conjugates (ADCs) of N,N-dialkylauristatins that are directed against the target C4.4a, to active metabolites of these ADCs, to processes for preparing these ADCs, to the use of these ADCs for treating and/or preventing illnesses, and also to the use of these ADCs for producing medicaments for treating and/or preventing illnesses, more particularly hyperproliferative and/or angiogenic diseases such as, for example, cancer diseases. Such treatments may be practiced as a monotherapy or else in combination with other medicaments or further therapeutic measures.

Binder-drug conjugates (ADCs) and use thereof

Growing community of inventors

Leverkusen, Germany

Sandra Bruder